PharmAthene Reports First Quarter 2011 Financial and Operating Results

Thursday, May 12, 2011 General News
Email Print This Page Comment
Font : A-A+

PHARMATHENE, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended March 31,

2011

2010

Revenue

$

6,337,722

$

3,116,553

Operating expenses:

Research and development

5,820,374

4,952,393

General and administrative

4,939,654

5,325,422

Depreciation and amortization

117,629

245,258

Total operating expenses

10,877,657

10,523,073

Loss from operations

(4,539,935)

(7,406,520)

Other income (expense):

Interest income

3,154

3,483

Interest expense

(15,435)

(948,150)

Other income (expense)

(11,906)

139,422

Change in market value of derivative instruments

2,488,465

267,496

Total other income (expense)

2,464,278

(537,749)

Net loss

$

(2,075,657)

$

(7,944,269)

Basic and diluted net loss per share

$

(0.04)

$

(0.28)

Weighted average shares used in calculation of basic and diluted net loss per share

46,276,874

28,172,802



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook